Oxford BioMedica PLC (OXBDF)

[marcusl2]

University of Pennsylvania, told HemOnc Today. “I would really like to see eventual approval for adult ALL next. The large multicenter trials haven’t been done, but there are so much preliminary data that it’s hard to envision these therapies won’t be tested and approved.”

Following adult ALL, focus should be on CLL and myeloma, Porter said.

“To me, there is no difference between CLL and non-Hodgkin lymphoma,” he said. “It’s solely a matter of resources to do larger clinical trials and show efficacy. Those are the low-hanging fruit. This provides therapy for an incredible unmet need when there is nothing else.”

Novartis is continuing studies of tisagenlecleucel in DLBCL, ALL and relapsed or refractory follicular lymphoma. Other CAR T-cell therapies in Novartis’s pipeline include targeting CD19 in CLL, anti-B-cell maturation antigen (BCMA) CAR T for multiple myeloma, anti-EGFRvIII CAR T for recurrent glioblastoma, and CAR-T-Meso for advanced ovarian cancer and mesothelioma, according to Touchon.

HTTPS://www.healio.com/hematology-oncology/leukemia/news/print/hemonc-today/%7Bbce73f3b-0172-4e05-a109-ba531502b2c6%7D/reimbursement-remains-difficult-issue-in-car-t-cell-therapy-rollout